How to Switch from Adderall to Strattera (Atomoxetine)

Strattera (atomoxetine) is a selective norepinephrine reuptake inhibitor (NRI) — completely different from stimulants like Adderall. It was the first non-stimulant medication FDA-approved for ADHD (2002) and remains one of the most widely prescribed alternatives to stimulants.

Key reasons patients switch from Adderall to Strattera:

• Anxiety comorbidity — Up to 50% of adults with ADHD also have an anxiety disorder. Stimulants can worsen anxiety symptoms, while Strattera often improves them. Multiple studies show Strattera reduces both ADHD and anxiety symptoms simultaneously.
• Substance use history — Strattera has zero abuse potential. It's not a controlled substance, doesn't produce euphoria, and can't be misused. For patients in recovery or with a history of stimulant misuse, it's the gold standard alternative.
• 24/7 coverage — Unlike stimulants that wear off after 4–14 hours, Strattera works around the clock. This means better symptom control in the evenings, on weekends, and during the night — helping with executive function at all times, not just during "medication hours."
• No rebound or crash — Strattera doesn't cause the afternoon crash, rebound irritability, or mood swings associated with stimulant wear-off.
• Stimulant intolerance — Some patients experience unacceptable side effects on stimulants: severe appetite suppression, insomnia, cardiac palpitations, or emotional blunting. Strattera avoids these stimulant-specific effects.
• Tic disorders — Strattera is safe for patients with comorbid Tourette syndrome or tic disorders, whereas stimulants may exacerbate tics in some individuals.

The main trade-off: Strattera takes 4–6 weeks to reach full therapeutic effect, whereas Adderall works within an hour. This delayed onset requires patience and a carefully managed transition period. If you'd prefer to stay on a stimulant but want longer duration, switching from Adderall to Vyvanse is another popular option. You can also compare Strattera to the newer non-stimulant Qelbree in our Strattera vs. Qelbree comparison.

Because Strattera takes weeks to reach therapeutic levels, abruptly stopping Adderall and starting Strattera would leave you without adequate ADHD symptom control for a month or more. A cross-taper — overlapping both medications — is the recommended approach:

Week 1–2: Initiation Phase

• Start Strattera at 40mg once daily (take in the morning with food to reduce nausea)
• Continue Adderall at your full current dose
• Monitor for nausea, headache, or drowsiness from Strattera — these are common initial side effects

Week 3: Strattera Dose Increase

• Increase Strattera to 80mg once daily (or split into 40mg twice daily if nausea is an issue)
• Begin reducing Adderall by 25–50%
• You may notice some decrease in focus as Adderall is reduced — this is expected and temporary

Week 4: Complete the Transition

• If tolerating 80mg well, increase Strattera to target dose (80–100mg/day for most adults; max 100mg/day or 1.4mg/kg/day)
• Reduce Adderall to 25% of original dose or discontinue entirely

Week 5–6: Full Strattera Monotherapy

• Stop Adderall completely
• Strattera should be approaching full therapeutic effect
• Don't judge Strattera's full effectiveness until you've been at target dose for at least 4 weeks

Important: The cross-taper timeline should be individualized. Patients with severe ADHD symptoms may need a slower Adderall taper. Patients who tolerate Strattera well may move faster. Always follow your prescriber's specific instructions. If you're also exploring stimulant alternatives, see our guide on switching from Ritalin to Vyvanse.

Understanding Strattera's effectiveness profile is crucial for setting realistic expectations — it works very differently from stimulants:

Timeline of effects:

• Week 1–2: Minimal ADHD symptom improvement. You may notice mild alertness or a calming effect, but don't expect the immediate "switch on" that stimulants provide.
• Week 3–4: Gradual improvement in sustained attention, working memory, and impulse control. Many patients describe it as "the noise in my head getting quieter."
• Week 6–8: Full therapeutic effect. Studies show statistically significant symptom reduction by this point, with effect sizes of 0.4–0.7 (moderate) compared to 0.8–1.0 for stimulants.
• Month 3+: Continued improvement in emotional regulation and executive function. Strattera's benefits in emotional dysregulation may actually exceed those of stimulants.

Response rates: Approximately 60–70% of patients respond to Strattera, compared to 70–80% for stimulants. While the overall response rate is slightly lower, many patients who failed stimulants respond well to Strattera — the mechanisms are entirely different.

Where Strattera excels:

• Emotional regulation — Strattera often improves frustration tolerance, emotional reactivity, and mood stability better than stimulants
• Evening and morning function — 24/7 coverage means better organization, planning, and impulse control outside of "business hours"
• Comorbid anxiety — Dual benefit in treating both ADHD and anxiety symptoms

Where stimulants are superior: For pure cognitive focus and task initiation, stimulants generally have a larger effect size. If raw focus during work hours is your primary concern and you don't have contraindications to stimulants, Strattera may feel "softer." In that case, a long-acting stimulant like Vyvanse may be a better fit — see our Adderall to Vyvanse guide.

Strattera and Adderall have fundamentally different side effect profiles because they work through different mechanisms. Here's a comprehensive comparison:

Side effects that typically improve when switching to Strattera:

• Appetite suppression: Strattera has minimal effect on appetite compared to stimulants. Most patients regain normal eating patterns within 1–2 weeks of stopping Adderall.
• Insomnia: Strattera doesn't interfere with sleep onset or sleep architecture. In fact, many patients report improved sleep quality due to the absence of stimulant-related insomnia.
• Cardiovascular stimulation: While Strattera can mildly increase heart rate and blood pressure, the effect is generally less pronounced than with amphetamines.
• Emotional blunting: Some patients on stimulants report feeling "flat" or emotionally disconnected. Strattera doesn't cause this effect.
• Rebound and crash: Completely eliminated — Strattera has a steady-state pharmacokinetic profile.

New side effects to watch for with Strattera:

• Nausea (35–40%): The most common side effect, especially during titration. Taking Strattera with food and starting at a low dose significantly reduces this. Typically resolves within 1–2 weeks.
• Fatigue/drowsiness (10–15%): Some patients experience initial tiredness. If this occurs, taking Strattera in the evening may help.
• Decreased libido / sexual side effects (5–10%): Atomoxetine can affect sexual function in some adults, including erectile dysfunction and decreased libido.
• Mood changes during titration: Irritability or mood swings may occur during dose adjustments. These are typically transient.

FDA Black Box Warning: Strattera carries a black box warning for suicidal ideation in children and adolescents (not adults). While this is serious, the risk is small (~0.4%) and limited to the pediatric population. Adults should still monitor for unusual mood changes during the first few months.

Liver function: Rare cases of severe liver injury have been reported. Your doctor may order baseline liver function tests. Seek immediate medical attention if you experience jaundice (yellowing of skin/eyes), dark urine, or upper abdominal pain. For a side-by-side look at non-stimulant options, see our Strattera vs. Qelbree comparison.